We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Angion Biomedica Signs Licensing Option with Memorial Sloan Kettering Cancer Center

News   Jan 09, 2009

 
Angion Biomedica Signs Licensing Option with Memorial Sloan Kettering Cancer Center
 
 
 

RELATED ARTICLES

Increasing the Odds of Synthetic Chemistry Success

News

Chemists show how analyzing previously published chemical reaction data can predict how hypothetical reactions may proceed, narrowing the range of conditions chemists need to explore. Their algorithmic prediction process, which includes aspects of machine learning, can save valuable time and resources in chemical research.

READ MORE

“Semi-synthetic” Bacteria Churn Out Proteins Containing Unnatural Amino Acids

News

Researchers have optimized a semi-synthetic bacteria to efficiently produce proteins containing unnatural amino acids.

READ MORE

Larger, Earlier Drug Trials Needed to Fight Alzheimer's

News

There are currently no drugs that stop or inhibit Alzheimer's disease. Despite drug trials showing plaque reduction in the brain, the patients' cognitive function did not improve. Would the results be different if it were possible to design studies that intervene much earlier on in the disease, before cognition is affected?

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE